Sun, Dec 28, 2014, 6:37 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

MiMedx Group, Inc. Message Board

  • strut1702 strut1702 Sep 5, 2013 11:57 AM Flag

    MDXG vs OSIR

    MDXG is undervalued compared to OSIR and generates more cash. Epifix is the moneymaker for MDXG. Grafix for OSIR.

    OSIR soared on a Grafix study recently. But the buzz on the streets are that the sales force for MDXG are OUTSELLING the Grafix people. The market share for MDXG is coming from wound graft leaders such as Dermagraft and Apligraf. Anecdotal experience matters to physicians and Epifix is their choice.

    Many will argue that Epifix is superior to Grafix. But it doesn't really matter at this point. Focus on the BIG PICTURE:

    The diabetic ulcer market is worth 1-2 billion. That is where solutions are most needed immediately.

    This is where MDXG and OSIR will thrive. There is room for both.

11.29+0.120(+1.07%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.